Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis.
Open Access
- 7 February 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 47 (1) , 36-43
- https://doi.org/10.1002/art1.10159
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugsArthritis & Rheumatism, 1998
- Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugsJournal of General Internal Medicine, 1996
- The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid ArthritisPharmacoEconomics, 1996
- Preventing NSAID-Induced Gastrointestinal ToxicityPharmacoEconomics, 1995
- Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory DrugsAnnals of Internal Medicine, 1991
- Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugsPublished by Oxford University Press (OUP) ,1990
- FDA arthritis advisory committee meeting: Postmarketing surveillance of nonsteroidal antiinflammatory drugsArthritis & Rheumatism, 1985